{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:30:03Z","timestamp":1793831403157,"version":"4.6.1"},"reference-count":205,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Type 2 diabetes mellitus (T2DM), a prevalent chronic disease affecting over 400 million people globally, is driven by genetic and environmental factors. The pathogenesis involves insulin resistance and \u03b2-cell dysfunction, mediated by mechanisms such as the dedifferentiation of \u03b2-cells, mitochondrial dysfunction, and oxidative stress. Treatment should be based on non-pharmacological therapy. Strategies such as increased physical activity, dietary modifications, cognitive-behavioral therapy are important in maintaining normal glycemia. Advanced therapies, including SGLT2 inhibitors and GLP-1 receptor agonists, complement these treatments and offer solid glycemic control, weight control, and reduced cardiovascular risk. Complications of T2DM, such as diabetic kidney disease, retinopathy, and neuropathy, underscore the need for early diagnosis and comprehensive management to improve patient outcomes and quality of life.<\/jats:p>","DOI":"10.3390\/ijms26031094","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T03:54:27Z","timestamp":1737950067000},"page":"1094","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":371,"title":["Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications"],"prefix":"10.3390","volume":"26","author":[{"given":"Ewelina","family":"M\u0142ynarska","sequence":"first","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5502-0335","authenticated-orcid":false,"given":"Witold","family":"Czarnik","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasza","family":"Dzie\u017ca","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika","family":"J\u0119draszak","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0447-8510","authenticated-orcid":false,"given":"Gabriela","family":"Majchrowicz","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Prusinowski","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3490-3480","authenticated-orcid":false,"given":"Magdalena","family":"Stabrawa","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacek","family":"Rysz","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Hypertension and Family Medicine, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Franczyk","sequence":"additional","affiliation":[{"name":"Department of Nephrocardiology, Medical University of Lodz, Ul. Zeromskiego 113, 90-549 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,1,27]]},"reference":[{"key":"ref_1","unstructured":"NCD Risk Factor Collaboration (NCD-RisC) (2024). Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: A pooled analysis of 1108 population-representative studies with 141 million participants. Lancet, 404, 2077\u20132093."},{"key":"ref_2","unstructured":"GBD 2021 Diabetes Collaborators (2023). Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021. Lancet, 402, 203\u2013234. Erratum in Lancet 2023, 402, 1132."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1478-7954-8-29","article-title":"Projection of the year 2050 burden of diabetes in the US adult population: Dynamic modeling of incidence, mortality, and prediabetes prevalence","volume":"8","author":"Boyle","year":"2010","journal-title":"Popul. Health Metr."},{"key":"ref_4","unstructured":"International Diabetes Federation (2020, January 31). IDF Diabetes Atlas 10th Edition. Available online: https:\/\/diabetesatlas.org\/."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S2213-8587(17)30186-9","article-title":"Type 2 diabetes in adolescents and young adults","volume":"6","author":"Lascar","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1016\/j.cell.2024.06.029","article-title":"Diabetes mellitus-Progress and opportunities in the evolving epidemic","volume":"187","author":"Abel","year":"2024","journal-title":"Cell"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s12020-024-03772-w","article-title":"Early onset type 2 diabetes mellitus: An update","volume":"85","author":"Strati","year":"2024","journal-title":"Endocrine"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"(2013). American Diabetes Association. Standards of medical care in diabetes\u20142013. Diabetes Care, 36, S11\u2013S66.","DOI":"10.2337\/dc13-S011"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jdi.13679","article-title":"Diversity of pathophysiology in type\u20092 diabetes shown by islet pathology","volume":"13","author":"Mizukami","year":"2022","journal-title":"J. Diabetes Investig."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1016\/S0140-6736(05)61032-X","article-title":"Type 2 diabetes: Principles of pathogenesis and therapy","volume":"365","author":"Stumvoll","year":"2005","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Cerf, M.E. (2013). Beta cell dysfunction and insulin resistance. Front. Endocrinol., 4.","DOI":"10.3389\/fendo.2013.00037"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","article-title":"Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes","volume":"52","author":"Butler","year":"2003","journal-title":"Diabetes"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1007\/s00125-010-1850-5","article-title":"Glucolipotoxicity age-dependently impairs beta cell function in rats despite a marked increase in beta cell mass","volume":"53","author":"Zarrouki","year":"2010","journal-title":"Diabetologia"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1210\/jc.2014-1425","article-title":"\u03b2-cell failure in type 2 diabetes: Postulated mechanisms and prospects for prevention and treatment","volume":"99","author":"Halban","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/pedi.12137","article-title":"High fat programming of beta cell compensation, exhaustion, death and dysfunction","volume":"16","author":"Cerf","year":"2015","journal-title":"Pediatr. Diabetes"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11892-019-1196-4","article-title":"The Beta Cell in Type 2 Diabetes","volume":"19","author":"Christensen","year":"2019","journal-title":"Curr. Diab. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.4161\/isl.27494","article-title":"\u03b2-cell dedifferentiation in diabetes is important, but what is it?","volume":"5","author":"Weir","year":"2013","journal-title":"Islets"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1172\/JCI65390","article-title":"Inactivation of specific \u03b2 cell transcription factors in type 2 diabetes","volume":"123","author":"Guo","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"4969","DOI":"10.1128\/MCB.25.12.4969-4976.2005","article-title":"MafA is a key regulator of glucose-stimulated insulin secretion","volume":"25","author":"Zhang","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.2337\/db12-1001","article-title":"Conversion of mature human \u03b2-cells into glucagon-producing \u03b1-cells","volume":"62","author":"Spijker","year":"2013","journal-title":"Diabetes"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3628","DOI":"10.1210\/jc.2016-2496","article-title":"Increased Frequency of Hormone Negative and Polyhormonal Endocrine Cells in Lean Individuals with Type 2 Diabetes","volume":"101","author":"Dhawan","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_22","first-page":"244","article-title":"Pancreatic \u03b2 cell identity requires continual repression of non-\u03b2 cell programs","volume":"127","author":"Bender","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cmet.2013.12.002","article-title":"Pdx1 maintains \u03b2 cell identity and function by repressing an \u03b1 cell program","volume":"19","author":"Gao","year":"2014","journal-title":"Cell Metab."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1210\/jc.2015-2860","article-title":"Evidence of \u03b2-Cell Dedifferentiation in Human Type 2 Diabetes","volume":"101","author":"Cinti","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.2337\/db14-1752","article-title":"Loss of \u03b2-Cell Identity Occurs in Type 2 Diabetes and Is Associated with Islet Amyloid Deposits","volume":"64","author":"Spijker","year":"2015","journal-title":"Diabetes"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"89","DOI":"10.4161\/isl.2.2.11025","article-title":"Identification of genes selectively disallowed in the pancreatic islet","volume":"2","author":"Pullen","year":"2010","journal-title":"Islets"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Martin, D., and Grapin-Botton, A. (2017). The Importance of REST for Development and Function of Beta Cells. Front. Cell Dev. Biol., 5.","DOI":"10.3389\/fcell.2017.00012"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.cmet.2018.12.005","article-title":"Combined Inhibition of DYRK1A, SMAD, and Trithorax Pathways Synergizes to Induce Robust Replication in Adult Human Beta Cells","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.mce.2012.08.003","article-title":"The molecular mechanisms of pancreatic \u03b2-cell glucotoxicity: Recent findings and future research directions","volume":"364","author":"Bensellam","year":"2012","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1210\/er.2007-0023","article-title":"Glucolipotoxicity: Fuel excess and beta-cell dysfunction","volume":"29","author":"Poitout","year":"2008","journal-title":"Endocr. Rev."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.redox.2017.01.013","article-title":"Mitochondrial dynamics in type 2 diabetes: Pathophysiological implications","volume":"11","author":"Rocha","year":"2017","journal-title":"Redox. Biol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2337\/db18-0304","article-title":"Pancreatic \u03b2-Cell Rest Replenishes Insulin Secretory Capacity and Attenuates Diabetes in an Extreme Model of Obese Type 2 Diabetes","volume":"68","author":"Boland","year":"2019","journal-title":"Diabetes"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.soard.2011.08.014","article-title":"Ten-year duration of type 2 diabetes as prognostic factor for remission after sleeve gastrectomy","volume":"7","author":"Casella","year":"2011","journal-title":"Surg. Obes. Relat. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1097\/00000658-200211000-00003","article-title":"Potential of surgery for curing type 2 diabetes mellitus","volume":"236","author":"Rubino","year":"2002","journal-title":"Ann. Surg."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/978-90-481-3271-3_9","article-title":"Role of mitochondria in beta-cell function and dysfunction","volume":"654","author":"Maechler","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/j.cellsig.2016.05.007","article-title":"Bridges between mitochondrial oxidative stress, ER stress and mTOR signaling in pancreatic \u03b2 cells","volume":"28","author":"Wang","year":"2016","journal-title":"Cell Signal."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.beem.2012.05.004","article-title":"Mitochondrial dynamics and morphology in beta-cells","volume":"26","author":"Stiles","year":"2012","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00109-004-0533-4","article-title":"Antioxidant enzyme activity and mRNA expression in the islets of Langerhans from the BB\/S rat model of type 1 diabetes and an insulin-producing cell line","volume":"82","author":"Sigfrid","year":"2004","journal-title":"J. Mol. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"673","DOI":"10.2337\/db07-1056","article-title":"Mitochondrial reactive oxygen species are obligatory signals for glucose-induced insulin secretion","volume":"58","author":"Leloup","year":"2009","journal-title":"Diabetes"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.fct.2016.12.016","article-title":"The impairment of glucose-stimulated insulin secretion in pancreatic \u03b2-cells caused by prolonged glucotoxicity and lipotoxicity is associated with elevated adaptive antioxidant response","volume":"100","author":"Fu","year":"2017","journal-title":"Food Chem. Toxicol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.dsx.2018.11.056","article-title":"Higher levels of thioredoxin interacting protein (TXNIP) in patients with prediabetes compared to obese normoglycemic subjects","volume":"13","author":"Gateva","year":"2019","journal-title":"Diabetes Metab. Syndr."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1097\/MED.0000000000000391","article-title":"Diabetes pathogenic mechanisms and potential new therapies based upon a novel target called TXNIP","volume":"25","author":"Thielen","year":"2018","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1146\/annurev-biochem-072909-095555","article-title":"Endoplasmic reticulum stress and type 2 diabetes","volume":"81","author":"Back","year":"2012","journal-title":"Annu. Rev. Biochem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1242\/jcs.00408","article-title":"The unfolded protein response","volume":"116","author":"Liu","year":"2003","journal-title":"J. Cell Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"8885","DOI":"10.1073\/pnas.1105564108","article-title":"Dual and opposing roles of the unfolded protein response regulated by IRE1alpha and XBP1 in proinsulin processing and insulin secretion","volume":"108","author":"Lee","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.devcel.2015.12.030","article-title":"When Less Is Better: ER Stress and Beta Cell Proliferation","volume":"36","author":"Yong","year":"2016","journal-title":"Dev. Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/nyas.13531","article-title":"Misfolded proinsulin in the endoplasmic reticulum during development of beta cell failure in diabetes","volume":"1418","author":"Arunagiri","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1016\/j.ajpath.2011.02.036","article-title":"\u03b2-cell loss and \u03b2-cell apoptosis in human type 2 diabetes are related to islet amyloid deposition","volume":"178","author":"Jurgens","year":"2011","journal-title":"Am. J. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.molmet.2017.04.002","article-title":"Opposing effects of prostaglandin E2 receptors EP3 and EP4 on mouse and human \u03b2-cell survival and proliferation","volume":"6","author":"Carboneau","year":"2017","journal-title":"Mol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.2337\/db12-0769","article-title":"Prostaglandin E2 receptor, EP3, is induced in diabetic islets and negatively regulates glucose- and hormone-stimulated insulin secretion","volume":"62","author":"Kimple","year":"2013","journal-title":"Diabetes"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/nm.4350","article-title":"Insulin action and resistance in obesity and type 2 diabetes","volume":"23","author":"Czech","year":"2017","journal-title":"Nat. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s11538-016-0181-1","article-title":"The Effects of Insulin Resistance on Individual Tissues: An Application of a Mathematical Model of Metabolism in Humans","volume":"78","author":"Pearson","year":"2016","journal-title":"Bull. Math. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K.B., Ostolaza, H., and Mart\u00edn, C. (2020). Pathophysiology of Type 2 Diabetes Mellitus. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176275"},{"key":"ref_54","first-page":"19","article-title":"Insulin and insulin resistance","volume":"26","author":"Wilcox","year":"2005","journal-title":"Clin. Biochem. Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"11G","DOI":"10.1016\/S0002-9149(02)02554-7","article-title":"Pathogenesis of skeletal muscle insulin resistance in type 2 diabetes mellitus","volume":"90","author":"Petersen","year":"2002","journal-title":"Am. J. Cardiol."},{"key":"ref_56","first-page":"8","article-title":"Cellular mechanism of insulin resistance in skeletal muscle","volume":"95","author":"Petersen","year":"2002","journal-title":"J. R. Soc. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"18677","DOI":"10.3390\/ijms151018677","article-title":"Molecular mechanisms for the regulation of insulin-stimulated glucose uptake by small guanosine triphosphatases in skeletal muscle and adipocytes","volume":"15","author":"Satoh","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Abdul-Ghani, M.A., and DeFronzo, R.A. (2010). Pathogenesis of insulin resistance in skeletal muscle. J. Biomed. Biotechnol., 2010.","DOI":"10.1155\/2010\/476279"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1172\/JCI88880","article-title":"Skeletal muscle inflammation and insulin resistance in obesity","volume":"127","author":"Wu","year":"2017","journal-title":"J. Clin. Investig."},{"key":"ref_60","first-page":"1764","article-title":"Effect of Physical activity on Insulin Resistance, Inflammation and Oxidative Stress in Diabetes Mellitus","volume":"7","author":"Venkatasamy","year":"2013","journal-title":"J. Clin. Diagn. Res."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.molmet.2019.12.014","article-title":"Mechanisms of insulin resistance related to white, beige, and brown adipocytes","volume":"34","author":"Czech","year":"2020","journal-title":"Mol. Metab."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00125-018-4777-x","article-title":"The many secret lives of adipocytes: Implications for diabetes","volume":"62","author":"Scherer","year":"2019","journal-title":"Diabetologia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41586-019-1797-8","article-title":"The integrative biology of type 2 diabetes","volume":"576","author":"Roden","year":"2019","journal-title":"Nature"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1089\/dia.2010.0240","article-title":"Validation of insulin sensitivity and secretion indices derived from the liquid meal tolerance test","volume":"13","author":"Maki","year":"2011","journal-title":"Diabetes Technol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.tem.2017.03.003","article-title":"Unraveling the Regulation of Hepatic Metabolism by Insulin","volume":"28","author":"Titchenell","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1042\/BST0351171","article-title":"Insulin action on the liver in vivo","volume":"35","author":"Cherrington","year":"2007","journal-title":"Biochem. Soc. Trans."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhep.2007.04.002","article-title":"Insulin resistance in hepatocytes and sinusoidal liver cells: Mechanisms and consequences","volume":"47","author":"Leclercq","year":"2007","journal-title":"J. Hepatol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/j.clinbiochem.2009.05.018","article-title":"Hepatic insulin resistance, metabolic syndrome and cardiovascular disease","volume":"42","author":"Meshkani","year":"2009","journal-title":"Clin. Biochem."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Gurung, M., Li, Z., You, H., Rodrigues, R., Jump, D.B., Morgun, A., and Shulzhenko, N. (2020). Role of gut microbiota in type 2 diabetes pathophysiology. EBioMedicine, 51.","DOI":"10.1016\/j.ebiom.2019.11.051"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jdi.12673","article-title":"Understanding the role of the gut ecosystem in diabetes mellitus","volume":"9","author":"Aw","year":"2018","journal-title":"J. Diabetes Investig."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1053\/j.gastro.2016.11.018","article-title":"Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-Like Receptor 4 Signaling to Nuclear Factor-\u03baB, and Up-regulating Expression of MicroRNA-21","volume":"152","author":"Yang","year":"2017","journal-title":"Gastroenterology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13073-017-0490-5","article-title":"A novel Ruminococcus gnavus clade enriched in inflammatory bowel disease patients","volume":"9","author":"Hall","year":"2017","journal-title":"Genome Med."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Kang, J.H., Yun, S.I., Park, M.H., Park, J.H., Jeong, S.Y., and Park, H.O. (2013). Anti-obesity effect of Lactobacillus gasseri BNR17 in high-sucrose diet-induced obese mice. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0054617"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s13668-020-00307-3","article-title":"Metabolites Linking the Gut Microbiome with Risk for Type 2 Diabetes","volume":"9","author":"Zhu","year":"2020","journal-title":"Curr. Nutr. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"162021","DOI":"10.1155\/2014\/162021","article-title":"Evidence for the gut microbiota short-chain fatty acids as key pathophysiological molecules improving diabetes","volume":"2014","author":"Puddu","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.cell.2013.12.016","article-title":"Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits","volume":"156","author":"Goncalves","year":"2014","journal-title":"Cell"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3920\/BM2010.0028","article-title":"The interaction of short-chain fatty acids with adipose tissue: Relevance for prevention of type 2 diabetes","volume":"1","author":"Roelofsen","year":"2010","journal-title":"Benef. Microbes"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1096\/fj.00-0359fje","article-title":"Anti-inflammatory effects of sodium butyrate on human monocytes: Potent inhibition of IL-12 and up-regulation of IL-10 production","volume":"14","author":"Osterreicher","year":"2000","journal-title":"FASEB J."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MCO.0b013e32833eebe5","article-title":"Butyrate and other short-chain fatty acids as modulators of immunity: What relevance for health?","volume":"13","author":"Meijer","year":"2010","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nrendo.2014.171","article-title":"Branched-chain amino acids in metabolic signalling and insulin resistance","volume":"10","author":"Lynch","year":"2014","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2337\/db23-0401","article-title":"Increased Plasma Branched Short-Chain Fatty Acids and Improved Glucose Homeostasis: The Microbiome and Insulin Longitudinal Evaluation Study (MILES)","volume":"73","author":"Aslamy","year":"2024","journal-title":"Diabetes"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1111\/obr.12699","article-title":"Pathways and mechanisms linking dietary components to cardiometabolic disease: Thinking beyond calories","volume":"19","author":"Stanhope","year":"2018","journal-title":"Obes. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/S2213-8587(20)30110-8","article-title":"Causes, consequences, and treatment of metabolically unhealthy fat distribution","volume":"8","author":"Stefan","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cmet.2017.07.008","article-title":"Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans","volume":"26","author":"Stefan","year":"2017","journal-title":"Cell Metab."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1038\/s41591-019-0563-7","article-title":"Contribution of genetics to visceral adiposity and its relation to cardiovascular and metabolic disease","volume":"25","author":"Karlsson","year":"2019","journal-title":"Nat. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"821","DOI":"10.2337\/dc13-1353","article-title":"Structural and functional properties of deep abdominal subcutaneous adipose tissue explain its association with insulin resistance and cardiovascular risk in men","volume":"37","author":"Marinou","year":"2014","journal-title":"Diabetes Care"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S2213-8587(24)00164-5","article-title":"Impact of higher BMI on cardiometabolic risk: Does height matter?","volume":"12","author":"Stefan","year":"2024","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1007\/s00125-019-04978-8","article-title":"Associations of short stature and components of height with incidence of type 2 diabetes: Mediating effects of cardiometabolic risk factors","volume":"62","author":"Wittenbecher","year":"2019","journal-title":"Diabetologia"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1210\/er.2010-0029","article-title":"Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes","volume":"32","author":"Norton","year":"2011","journal-title":"Endocr. Rev."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/dom.13650","article-title":"A review of the mechanism of action, metabolic profile and haemodynamic effects of sodium-glucose co-transporter-2 inhibitors","volume":"21","author":"Brown","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists: Established and emerging indications","volume":"398","author":"Brown","year":"2021","journal-title":"Lancet"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/oby.22066","article-title":"The Association Between the Dosage of SGLT2 Inhibitorand Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis","volume":"26","author":"Cai","year":"2018","journal-title":"Obesity"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.12578","article-title":"Energy balance and metabolic changes with sodium-glucose co-transporter 2 inhibition","volume":"18","author":"Rajeev","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","author":"Rossing","year":"2022","journal-title":"Kidney Int."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: Results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/dom.12670","article-title":"Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: Systematic review and network meta-analysis","volume":"18","author":"Zaccardi","year":"2016","journal-title":"Diabetes Obes Metab."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/dom.12825","article-title":"Urinary tract andgenital infections in patients with type 2 diabetes treated withsodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials","volume":"19","author":"Li","year":"2017","journal-title":"Diabetes Obes. Metab."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.1210\/en.2002-220405","article-title":"Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats","volume":"143","author":"Farilla","year":"2002","journal-title":"Endocrinology"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/dom.12596","article-title":"Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists","volume":"18","author":"Madsbad","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1210\/en.2008-0726","article-title":"Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell","volume":"150","author":"Lim","year":"2009","journal-title":"Endocrinology"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients with Type 2 Diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1530\/EJE-19-0566","article-title":"Management of endocrine disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?","volume":"181","author":"Nauck","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","article-title":"Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): A randomised, open-label, phase 3, non-inferiority trial","volume":"384","author":"Dungan","year":"2014","journal-title":"Lancet"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0 mg vs once-daily liraglutide 1\u00b72 mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Popoviciu, M.S., P\u0103duraru, L., Yahya, G., Metwally, K., and Cavalu, S. (2023). Emerging Role of GLP-1 Agonists in Obesity: A Comprehensive Review of Randomised Controlled Trials. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241310449"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1124\/pr.108.000604","article-title":"The role of incretins in glucose homeostasis and diabetes treatment","volume":"60","author":"Kim","year":"2008","journal-title":"Pharmacol. Rev."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"R\u00f6hrborn, D., Wronkowitz, N., and Eckel, J. (2015). DPP4 in Diabetes. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00386"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Singhal, S., Manikrao Patil, V., Verma, S., and Masand, N. (2024). Recent advances and structure-activity relationship studies of DPP-4 inhibitors as anti-diabetic agents. Bioorg. Chem., 146.","DOI":"10.1016\/j.bioorg.2024.107277"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1016\/S0140-6736(06)69705-5","article-title":"The incretin system: Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes","volume":"368","author":"Drucker","year":"2006","journal-title":"Lancet"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: From physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pan.2015.05.465","article-title":"Clinical use of GLP-1 agonists and DPP4 inhibitors","volume":"16","author":"Tuch","year":"2016","journal-title":"Pancreatology"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.2174\/1381612823666170307103222","article-title":"Antidiabetic Drugs and the Kidney","volume":"23","author":"Tsimihodimos","year":"2017","journal-title":"Curr. Pharm. Des."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e2116506119","DOI":"10.1073\/pnas.2116506119","article-title":"Structural determinants of dual incretin receptor agonism by tirzepatide","volume":"119","author":"Sun","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"102489","DOI":"10.1016\/j.cpcardiol.2024.102489","article-title":"Tirzepatide: A novel cardiovascular protective agent in type 2 diabetes mellitus and obesity","volume":"49","author":"Sardar","year":"2024","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e140532","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14831","article-title":"Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective","volume":"25","author":"Bailey","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s13300-020-00981-0","article-title":"The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials","volume":"12","author":"Min","year":"2021","journal-title":"Diabetes Ther."},{"key":"ref_121","first-page":"e17","article-title":"Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes","volume":"386","author":"Santulli","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): A double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes","volume":"385","author":"Davies","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.2174\/1381612826666200728144200","article-title":"Fighting Diabetes Mellitus: Pharmacological and Non-pharmacological Approaches","volume":"26","author":"Wang","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2174\/0115733998275876240125064716","article-title":"Unraveling the Therapeutic Potential of Muscle Strengthening Exercises for Reversing Diabetes Mellitus","volume":"21","author":"Samsudeen","year":"2025","journal-title":"Curr. Diabetes Rev."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Az\u00f3car-Gallardo, J., Ojeda-Aravena, A., B\u00e1ez-San Mart\u00edn, E., Herrera-Valenzuela, T., Tuesta, M., Gonz\u00e1lez-Rojas, L., Calvo-Rico, B., and Garc\u00eda-Garc\u00eda, J.M. (2024). Effect of a Concurrent Training Program with and Without Metformin Treatment on Metabolic Markers and Cardiorespiratory Fitness in Individuals with Insulin Resistance: A Retrospective Analysis. Biomolecules, 14.","DOI":"10.3390\/biom14111470"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/dom.16013","article-title":"Low-calorie, high-protein diets, regardless of protein source, improve glucose metabolism and cardiometabolic profiles in subjects with prediabetes or type 2 diabetes and overweight or obesity","volume":"27","author":"Cebollada","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"11961","DOI":"10.1039\/D4FO00337C","article-title":"A network meta-analysis of the comparative efficacy of different dietary approaches on glycaemic control and weight loss in patients with type 2 diabetes mellitus and overweight or obesity","volume":"15","author":"Yuan","year":"2024","journal-title":"Food Funct."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Kermansaravi, M., Chiappetta, S., Kassir, R., Bosco, A., Giudicelli, X., Lainas, P., and Safieddine, M. (2024). Efficacy of One Anastomosis Gastric Bypass Versus Sleeve Gastrectomy and Roux-en-Y Gastric Bypass for the Treatment of Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Obes. Surg., Epub ahead of print.","DOI":"10.1007\/s11695-024-07564-z"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Balasubaramaniam, V., and Pouwels, S. (2023). Remission of Type 2 Diabetes Mellitus (T2DM) after Sleeve Gastrectomy (SG), One-Anastomosis Gastric Bypass (OAGB), and Roux-en-Y Gastric Bypass (RYGB): A Systematic Review. Medicina, 59.","DOI":"10.3390\/medicina59050985"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.1111\/dom.15974","article-title":"Remission and relapse of diabetes after sleeve gastrectomy and one-anastomosis gastric bypass: The Tehran Obesity Treatment Study","volume":"26","author":"Sadeghi","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"109965","DOI":"10.1016\/j.diabres.2022.109965","article-title":"The efficacy of cognitive behavioral therapy-based intervention on patients with diabetes: A meta-analysis","volume":"189","author":"Li","year":"2022","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Yang, X., Li, Z., and Sun, J. (2020). Effects of Cognitive Behavioral Therapy-Based Intervention on Improving Glycaemic, Psychological, and Physiological Outcomes in Adult Patients with Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials. Front. Psychiatry, 11.","DOI":"10.3389\/fpsyt.2020.00711"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1111\/aphw.12441","article-title":"The effectiveness of mindfulness-based stress reduction (MBSR) on the mental health, HbA1C, and mindfulness of diabetes patients: A systematic review and meta-analysis of randomised controlled trials","volume":"15","author":"Fisher","year":"2023","journal-title":"Appl. Psychol. Health Well Being"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Baitule, S., Patel, A.H., Murthy, N., Sankar, S., Kyrou, I., Ali, A., Randeva, H.S., and Robbins, T. (2021). A Systematic Review to Assess the Impact of Hyperbaric Oxygen Therapy on Glycaemia in People with Diabetes Mellitus. Medicina, 57.","DOI":"10.3390\/medicina57101134"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e14530","DOI":"10.1111\/iwj.14530","article-title":"Quality of evidence supporting the role of hyperbaric oxygen therapy for diabetic foot ulcers","volume":"21","author":"Jiang","year":"2024","journal-title":"Int. Wound J."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"108862","DOI":"10.1016\/j.diabres.2021.108862","article-title":"Hyperbaric oxygen therapy for chronic diabetic foot ulcers: An overview of systematic reviews","volume":"176","author":"Li","year":"2021","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"106399","DOI":"10.1016\/j.phrs.2022.106399","article-title":"Probiotics and synbiotics supplementation improve glycemic control parameters in subjects with prediabetes and type 2 diabetes mellitus: A GRADE-assessed systematic review, meta-analysis, and meta-regression of randomized clinical trials","volume":"184","author":"Naseri","year":"2022","journal-title":"Pharmacol. Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12967-020-02213-2","article-title":"Effects of probiotics on type II diabetes mellitus: A meta-analysis","volume":"18","author":"Tao","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_140","first-page":"543","article-title":"The effects of probiotic and synbiotic supplementation on inflammation, oxidative stress, and circulating adiponectin and leptin concentration in subjects with prediabetes and type 2 diabetes mellitus: A GRADE-assessed systematic review, meta-analysis, and meta-regression of randomized clinical trials","volume":"62","author":"Naseri","year":"2023","journal-title":"Eur. J. Nutr."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11684-017-0569-9","article-title":"Non-genetic mechanisms of diabetic nephropathy","volume":"11","author":"Han","year":"2017","journal-title":"Front. Med."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.2215\/CJN.11491116","article-title":"Diabetic Kidney Disease: Challenges, Progress, and Possibilities","volume":"12","author":"Alicic","year":"2017","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10157-020-01881-0","article-title":"Nonproteinuric diabetic kidney disease","volume":"24","author":"Yamanouchi","year":"2020","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Guo, W., Song, Y., Sun, Y., Du, H., Cai, Y., You, Q., Fu, H., and Shao, L. (2022). Systemic immune-inflammation index is associated with diabetic kidney disease in Type 2 diabetes mellitus patients: Evidence from NHANES 2011-2018. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1071465"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1172\/JCI72271","article-title":"Molecular mechanisms of diabetic kidney disease","volume":"124","author":"Reidy","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"108357","DOI":"10.1016\/j.jdiacomp.2022.108357","article-title":"Present and future directions in diabetic kidney disease","volume":"36","author":"Limonte","year":"2022","journal-title":"J. Diabetes Complicat."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"15018","DOI":"10.1038\/nrdp.2015.18","article-title":"Diabetic kidney disease","volume":"1","author":"Thomas","year":"2015","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Ahmad, A.A., Draves, S.O., and Rosca, M. (2021). Mitochondria in Diabetic Kidney Disease. Cells, 10.","DOI":"10.3390\/cells10112945"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"e33366","DOI":"10.1097\/MD.0000000000033366","article-title":"Management of diabetic kidney disease: Where do we stand?: A narrative review","volume":"102","author":"Sindhu","year":"2023","journal-title":"Medicine"},{"key":"ref_150","first-page":"751","article-title":"Diabetic Kidney Disease: Diagnosis, Treatment, and Prevention","volume":"99","author":"McGrath","year":"2019","journal-title":"Am. Fam. Physician"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"112","DOI":"10.7861\/clinmed.2021-0792","article-title":"Diabetic retinopathy for the non-ophthalmologist","volume":"22","author":"Fung","year":"2022","journal-title":"Clin. Med."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Tan, T.E., and Wong, T.Y. (2023). Diabetic retinopathy: Looking forward to 2030. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.1077669"},{"key":"ref_153","doi-asserted-by":"crossref","unstructured":"Bryl, A., Mrugacz, M., Falkowski, M., and Zorena, K. (2022). The Effect of Diet and Lifestyle on the Course of Diabetic Retinopathy\u2014A Review of the Literature. Nutrients, 14.","DOI":"10.3390\/nu14061252"},{"key":"ref_154","first-page":"75","article-title":"Diabetic retinopathy: Early diagnosis and effective treatment","volume":"107","author":"Kollias","year":"2010","journal-title":"Dtsch. Arztebl. Int."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1111\/jdi.13480","article-title":"Update in the epidemiology, risk factors, screening, and treatment of diabetic retinopathy","volume":"12","author":"Lin","year":"2021","journal-title":"J Diabetes Investig."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: A systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob. Health"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.2147\/IJN.S294807","article-title":"Progress of Nanotechnology in Diabetic Retinopathy Treatment","volume":"16","author":"Liu","year":"2021","journal-title":"Int. J. Nanomed."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1007\/s00417-023-06134-w","article-title":"Refining vitrectomy for proliferative diabetic retinopathy","volume":"261","author":"Chen","year":"2023","journal-title":"Graefes Arch. Clin. Exp. Ophthalmol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41572-019-0092-1","article-title":"Diabetic neuropathy","volume":"5","author":"Feldman","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1212\/WNL.43.4.817","article-title":"The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy Study","volume":"43","author":"Dyck","year":"1993","journal-title":"Neurology"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1093\/brain\/awab079","article-title":"Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management","volume":"144","author":"Jensen","year":"2021","journal-title":"Brain"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s11910-014-0473-5","article-title":"Diabetic neuropathy: Mechanisms, emerging treatments, and subtypes","volume":"14","author":"Albers","year":"2014","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1016\/j.neuron.2017.02.005","article-title":"New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain","volume":"93","author":"Feldman","year":"2017","journal-title":"Neuron"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1097\/j.pain.0000000000001922","article-title":"Diabetic neuropathy and neuropathic pain: A (con)fusion of pathogenic mechanisms?","volume":"161","author":"Calcutt","year":"2020","journal-title":"Pain"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2337\/dc16-2042","article-title":"Diabetic Neuropathy: A Position Statement by the American Diabetes Association","volume":"40","author":"Boulton","year":"2017","journal-title":"Diabetes Care"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S1474-4422(12)70065-0","article-title":"Diabetic neuropathy: Clinical manifestations and current treatments","volume":"11","author":"Callaghan","year":"2012","journal-title":"Lancet Neurol."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Stefan, N., Yki-J\u00e4rvinen, H., and Neuschwander-Tetri, B.A. (2024). Metabolic dysfunction-associated steatotic liver disease: Heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol., Epub ahead of print.","DOI":"10.1016\/S2213-8587(24)00318-8"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cmet.2019.12.002","article-title":"Leveraging Human Genetics to Identify Potential New Treatments for Fatty Liver Disease","volume":"31","author":"Romeo","year":"2020","journal-title":"Cell Metab."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/MOG.0000000000000927","article-title":"Advances in the genetics of nonalcoholic fatty liver disease","volume":"39","author":"Ajmera","year":"2023","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"8263","DOI":"10.3748\/wjg.v23.i47.8263","article-title":"Clinical epidemiology and disease burden of nonalcoholic fatty liver disease","volume":"23","author":"Perumpail","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_171","doi-asserted-by":"crossref","unstructured":"(2018). American Diabetes Association. 8. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2018. Diabetes Care, 41, S73\u2013S85.","DOI":"10.2337\/dc18-S008"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2337\/diacare.29.04.06.dc05-1433","article-title":"High Risk of Cardiovascular Disease in Patients with Type 1 Diabetes in the UK","volume":"29","author":"Fuller","year":"2006","journal-title":"Diabetes Care"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2337\/diacare.16.2.434","article-title":"Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial","volume":"16","author":"Stamler","year":"1993","journal-title":"Diabetes Care"},{"key":"ref_174","unstructured":"Lanza, G.A., and Crea, F. (2010). Medicina Interna Sistematica, Elselvier Italia srl. [6th ed.]. Cardiopatia ischemica; Edra-Masson."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s00395-013-0387-4","article-title":"Role of genetic polymorphisms of ion channels in the pathophysiology of coronary microvascular dysfunction and ischemic heart disease","volume":"108","author":"Fedele","year":"2013","journal-title":"Basic Res. Cardiol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/JCN.0000000000000351","article-title":"Symptoms suggestive of acute coronary syndrome: When is sex important?","volume":"32","author":"DeVon","year":"2017","journal-title":"J. Cardiovasc. Nurs."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1161\/CIR.0b013e31820a55f5","article-title":"Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association","volume":"123","author":"Heidenreich","year":"2011","journal-title":"Circulation"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1161\/STROKEAHA.113.001318","article-title":"Diabetes mellitus: A risk factor for ischemic stroke in a large biracial population","volume":"44","author":"Khoury","year":"2013","journal-title":"Stroke"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"e3564","DOI":"10.1136\/bmj.e3564","article-title":"Effect of pre-diabetes on future risk of stroke: Meta-analysis","volume":"344","author":"Lee","year":"2012","journal-title":"BMJ"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1161\/STROKEAHA.118.022863","article-title":"Predicting Early Mortality of Acute Ischemic Stroke","volume":"50","author":"Gattringer","year":"2019","journal-title":"Stroke"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1503\/cmaj.140355","article-title":"Diagnosis and management of acute ischemic stroke: Speed is critical","volume":"187","author":"Musuka","year":"2015","journal-title":"CMAJ"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jstrokecerebrovasdis.2010.02.022","article-title":"Presenting symptoms and onset-to-arrival time in patients with acute stroke and transient ischemic attack","volume":"20","author":"Gargano","year":"2011","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1177\/1747493019896958","article-title":"Frequency of anxiety after stroke: An updated systematic review and meta-analysis of observational studies","volume":"15","author":"Knapp","year":"2020","journal-title":"Int. J. Stroke"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1161\/STROKEAHA.119.023552","article-title":"Poststroke Fatigue","volume":"50","author":"Paciaroni","year":"2019","journal-title":"Stroke"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000375397","article-title":"Post stroke pain: Identification, assessment, and therapy","volume":"39","author":"Harrison","year":"2015","journal-title":"Cerebrovasc. Dis."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes","volume":"44","author":"Marx","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5853\/jos.2022.02306","article-title":"Diabetes and stroke: What are the connections?","volume":"25","author":"Mosenzon","year":"2023","journal-title":"J. Stroke"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1007\/s00125-016-4065-6","article-title":"Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial","volume":"59","author":"Oellgaard","year":"2016","journal-title":"Diabetologia"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41572-019-0118-8","article-title":"Ischaemic stroke","volume":"5","author":"Campbell","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1706442","article-title":"Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct","volume":"378","author":"Nogueira","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1007\/s00415-014-7291-1","article-title":"Progressing haemorrhagic stroke: Categories, causes, mechanisms and managements","volume":"261","author":"Chen","year":"2014","journal-title":"J. Neurol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"312","DOI":"10.2174\/1871527320666210223145112","article-title":"Intracerebral hemorrhage and diabetes mellitus: Blood-brain barrier disruption, pathophysiology and cognitive impairments","volume":"20","author":"Bahadar","year":"2021","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"e005760","DOI":"10.1161\/JAHA.117.005760","article-title":"Persistent hyperglycemia is associated with increased mortality after intracerebral hemorrhage","volume":"6","author":"Wu","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1161\/STROKEAHA.121.034928","article-title":"Effect of moderate and severe persistent hyperglycemia on outcomes in patients with intracerebral hemorrhage","volume":"53","author":"Qureshi","year":"2022","journal-title":"Stroke"},{"key":"ref_195","doi-asserted-by":"crossref","unstructured":"Achim, A., Stanek, A., Homorodean, C., Spinu, M., Onea, H.L., Laz\u0103r, L., Marc, M., Ruzsa, Z., and Olinic, D.M. (2022). Approaches to Peripheral Artery Disease in Diabetes: Are There Any Differences?. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19169801"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1532-5415.2010.02941.x","article-title":"Leg symptom categories and rates of mobility decline in peripheral arterial disease","volume":"58","author":"McDermott","year":"2010","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_197","first-page":"645","article-title":"The diagnosis of ischaemic heart pain and intermittent claudication in field surveys","volume":"27","author":"Rose","year":"1962","journal-title":"Bull. World Health Organ."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/archinte.163.12.1469","article-title":"The prevalence of peripheral arterial disease in a racially diverse population","volume":"163","author":"Collins","year":"2003","journal-title":"Arch. Intern. Med."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1161\/CIRCULATIONAHA.105.548099","article-title":"Exertional leg pain in patients with and without peripheral arterial disease","volume":"112","author":"Wang","year":"2005","journal-title":"Circulation"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1161\/CIRCRESAHA.121.318535","article-title":"Epidemiology of Peripheral Artery Disease and Polyvascular Disease","volume":"128","author":"Aday","year":"2021","journal-title":"Circ. Res."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jdiacomp.2016.03.033","article-title":"Amputations and mortality in in-hospital treated patients with peripheral artery disease and diabetic foot syndrome","volume":"30","author":"Malyar","year":"2016","journal-title":"J. Diabetes Complicat."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1056\/NEJM200105243442108","article-title":"Medical treatment of peripheral arterial disease and claudication","volume":"344","author":"Hiatt","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.ijcard.2012.03.042","article-title":"Type 2 diabetes and the progression of visualized atherosclerosis to clinical cardiovascular events","volume":"167","author":"Saely","year":"2013","journal-title":"Int. J. Cardiol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1136\/heartjnl-2015-309076","article-title":"Contemporary evaluation and management of lower extremity peripheral artery disease","volume":"102","author":"Foley","year":"2016","journal-title":"Heart"},{"key":"ref_205","first-page":"e726","article-title":"2016 AHA\/ACC guideline on the management of patients with lower extremity peripheral artery disease: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"135","author":"Gornik","year":"2017","journal-title":"Circulation"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/3\/1094\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:36:59Z","timestamp":1759919819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/3\/1094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,27]]},"references-count":205,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["ijms26031094"],"URL":"https:\/\/doi.org\/10.3390\/ijms26031094","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,27]]}}}